Novartis Ag

Sandoz Gmbh

Joachim Nozulak

David Orain

Hans Allgeier

Dominik Feuerbach

Manuel Koller

Henri Mattes

Wolfgang Froestl

Johanne Renaud

Philipp Floersheim

Yves Auberson

David Carcache

Jörg Kallen

Christel Guibourdenche

Marina Tintelnot-Blomley

Thomas Josef Troxler

Silvio Ofner

Joerg Kallen

Rudolf K Giger

Bernard Lucien Roy

Nicolas Soldermann

Christina Hebach

Thomas Zoller

Max Peter Seiler

Leo Widler

Werner Müller

Ralf Glatthar

Jean-Marie Vigouret

Vittorio Rasetti

Dieter Oser

Andre Sauter

The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4. 

Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them. 

4-tolyl-ethynyl-octahydro-indole-1-ester derivatives

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein Rand Rare as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy

The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.

Quinazoline derivatives

N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide

The invention relates to compound of the formula I wherein the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Organic compounds

The invention provides compounds of formula (I) wherein

Acetylene derivatives

Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands

The invention provides compounds of formula (I) wherein R, R, Rand A are as defined in the description, and the preparation thereof. The compounds of formula (I) have high affinity as &#x3b1;adrenoceptors and hence are useful as pharmaceuticals.

1,3 disubstituted pyrrolidines as &#x3b1;-2-adrenoceptor antagonists

The invention provides compounds of formula (I) wherein n, A, R , R and R are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.

Azabicyclic carbamates and their use as &agr;-7 nicotinic acetylcholine receptor agonists

Compounds of formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, are useful for the treatment of conditions associated with cerebral ischaemia, e.g. stroke.

Use of naphthoxazines for the treatment of conditions associated with

3,4,4a,5,10,10a-hexahydro-2H-naphth[2,3-b]-1,4-oxazines are useful as psychostimulating and antidepressant agents.

Naphthoxazines and their use as psychostimulating and antidepressant

Growing community of inventors

Heitersheim, Germany

Joachim Nozulak